Literature DB >> 1615891

Weight loss and 2-y follow-up for 80 morbidly obese patients treated with intensive very-low-calorie diet and an education program.

J W Anderson1, V L Brinkman, C C Hamilton.   

Abstract

Eighty morbidly obese individuals consecutively enrolled in a comprehensive very-low-calorie diet (VLCD) program were evaluated. Patients' mean initial body mass index was 45.5 kg/m2 and they lost 35.3 kg in 26 wk. Serum total cholesterol, low-density-lipoprotein cholesterol, and triglycerides decreased by 15.0%, 17.0%, and 14%, respectively. Systolic and diastolic blood pressure decreased by 8.7% and 10.0%, respectively. The 46 individuals completing 2-y follow-up were maintaining 48.0 +/- 7.6% (means +/- SE) of their weight loss. Morbidly obese persons lost substantial amounts of weight using a comprehensive VLCD program, reduced risk factors associated with obesity, and had encouraging long-term results, with 48% of weight loss maintained at 2 y of follow-up.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615891     DOI: 10.1093/ajcn/56.1.244S

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  3 in total

Review 1.  Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care.

Authors:  J D Douketis; J W Feightner; J Attia; W F Feldman
Journal:  CMAJ       Date:  1999-02-23       Impact factor: 8.262

2.  Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial.

Authors:  Bret H Goodpaster; James P Delany; Amy D Otto; Lewis Kuller; Jerry Vockley; Jeannette E South-Paul; Stephen B Thomas; Jolene Brown; Kathleen McTigue; Kazanna C Hames; Wei Lang; John M Jakicic
Journal:  JAMA       Date:  2010-10-09       Impact factor: 56.272

Review 3.  Aggressive diets and lipid responses.

Authors:  Claudia Panzer; Caroline M Apovian
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.